Clinical trial · no report yet · Phase 2
BTC-BGB
Phase II Study of Sitravatinib in Combination With Tislelizumab in Patients With Advanced Biliary Tract Cancer
- NCT04727996 ↗
- Unknown
- Seoul National University Hospital
- Focused
We haven't built a report for this trial yet. This page shows the registry record and the public commentary we found that names the trial. A report reads that commentary and sets out what clinicians said about the trial, each point linked to its source. How reports are made.
Preliminary discovery
Commentary in our index that names this trial so far
Podcasts, YouTube videos and X posts we have indexed. A report screens them, searches for more and cites what clinicians said when it is built, so final coverage is set at build.
| Channel | Found | |
|---|---|---|
| X threads | 2 | |
| Bluesky threads | 1 |
The trial
ClinicalTrials.gov- Official title
- Phase II Study of Sitravatinib in Combination With Tislelizumab in Patients With Advanced Biliary Tract Cancer Who Have Failed to At Least 1 Prior Systemic Treatment
- Phase
- Phase 2
- Status
- Unknown
- Conditions
- Advanced Biliary Tract Cancer
- Interventions
- Sitravatinib; Tislelizumab
- Arms
- Sitravatinib/Tislelizumab · Experimental
- Enrollment
- 43
- Primary outcomes
- Disease control rate
- Sponsor
- Seoul National University Hospital with BeiGene
- Start
- Nov 1, 2020
- Primary completion
- Jul 31, 2023
- Results posted
- No
- Registry record
- NCT04727996 · updated Apr 19, 2024
Publications
linked from the registry- Yoon J, Lee CK, Kim JW, Kang B, Park SJ, Kim JW, Chon HJ, Choi HJ, Lee MA, Kim TY, Oh DY. Open-label, single-arm, phase II trial to investigate the efficacy of sitravatinib plus tislelizumab combination as a second-line treatment for advanced biliary tract cancer. J Hepatol. 2026 Apr;84(4):766-775. doi: 10.1016/j.jhep.2025.10.032. Epub 2025 Nov 24. PubMed 41297674